| Literature DB >> 33734563 |
Sebastian Kehrloesser1, Simon Oberst2,3, Willien Westerhuis4, Astrid Wendler1, Anke Wind5, Harriët Blaauwgeers4, Jean-Benoit Burrion6, Péter Nagy7, Gunnar Saeter2,8, Eva Gustafsson9, Paolo De Paoli10, József Lovey2,7, Claudio Lombardo2, Thierry Philip2,11, Dominique de Valeriola2,6, Marjet Docter5, Femke Boomsma12, Mahasti Saghatchian13,14, Marek Svoboda15, Irene Philip16, Francesco Monetti17, Henk Hummel4, Gordon McVie18, Renée Otter, Wim van Harten2,5,19,20.
Abstract
There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe's Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes' Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.Entities:
Keywords: accreditation; clinical trials; comprehensive cancer center; multidisciplinarity; quality standard; translational research
Mesh:
Year: 2021 PMID: 33734563 PMCID: PMC8096787 DOI: 10.1002/1878-0261.12950
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 6.603